QUALICOPC study: Luxembourgish data and presentation at the 19th WONCA EUROPE Conference, JULY 2014, Lisbon, Portugal and during the “Semaine Médicale de Lorraine 2014”, NOVEMBER 2014, Nancy, France.
ALVINA Study : Droste DW, Iliescu C, Vaillant M, Gantenbein M, De Bremaeker N, Lieunard C, Velez T, Meyer M, Guth T, Kuemmerle A, Chioti A: Advice on lifestyle changes (diet, red wine and physical activity) does not affect internal carotid and middle cerebral artery blood flow velocity in patients with carotid arteriosclerosis in a randomised controlled trial. Cerebrovasc Dis 2014; 37:368–375.
- Dr Anna Chioti - Advancing Public Awareness in Clinical Research, Association of Clinical Research Professionals (ACRP), APRIL 2014, San Antonio, Texas, USA
- Dr Anna Chioti & CIEC team - Outstanding Contribution to Luxembourg Healthcare and Life Sciences Community, Luxembourg Healthcare Summit JUNE 2014
- ECRIN annual conference in conjunction with celebration of International Clinical Trials Day and ECRAN Project conference in MAY 2014
- 6th Clinical research day dedicated to pharmacovigilance training in OCTOBER 2014
- EFGCP COURSE in JUNE 2014
- International Clinical Trials Day celebration in collaboration with the local hospitals (CHL, CHEM, Zitha, Kirchberg, CHdN) in MAY 2014
- FILM ON CLINICAL RESEARCH IN LUXEMBOURGISH with FNR in MAY 2014
- Participation to the Researchers Days in NOVEMBER 2014
- Launch of National Platform for EUPATI in DECEMBER 2014
- 1124 participants enrolled in 2014 (17 in pharma driven studies, 1107 in academic research studies)
- 16 new studies initiated (3 Compassionate Use Programs, 8 Pharma driven and 5 academic studies
- In 2 New therapeutic areas: Multiple Sclerosis, Parkinson Disease
- Collaborations
o Support to 4 national academic research projects
o 9 New collaborations with clinicians (CHL/CHEM/ChdN)
o Example for a successful CIEC/CHL collaboration: Both institutions were involved in an international pivotal clinical study with on the use of the drug "crizotinib" as first-line treatment against a form of lung cancer called adenocarcinoma in patients carrying a particular genetic mutation. The study, published in the "New England Journal of Medicine" in December, showed that the drug did shrink tumors, prolonged the survival of patients and was significantly more effective than conventional chemotherapy.
for articles/videos/studies
The articles can be sorted by therapeutic area or disease, but may also deal with more general topics not specifically related to a disease. These articles can be sorted as "other".
